Navigation Links
Sermo Study shows 70% of Specialists are Ready to Replace Warfarin
Date:12/3/2010

CAMBRIDGE, Mass., Dec. 3, 2010 /PRNewswire/ -- Sermo (http://www.sermo.com), the world's largest online community for physicians, today announced a free Sermo Report titled, "Potential Replacements for Coumadin (warfarin)." The report gathered feedback from physicians about awareness and understanding of these products and potential barriers to prescribing.

65% of all respondents were aware that a new product, Pradaxa (dabigatran etexilate mesylate), was currently available for use. Others indicated that while they may use Pradaxa, they are awaiting the approval of a similar drug, Xarelto (rivaroxaban).

This free Sermo Report polled 141 physicians across multiple specialties. Respondents discussed the importance of understanding how to reverse the effects of these medications when necessary, drug-drug interactions and dosing.  

Physicians shared their points of view on the advantages of replacing warfarin:

"...I think that this will be a watershed event in the treatment of non-valvular AF, and hopefully in other conditions, such as VTE, requiring anti-coagulation.  I hope that soon Coumadin will only be found in history books"  

-Family Medicine

"Dosing up to twice a day compared to once a day for warfarin could be acceptable since dabigatran needs no monitoring. Still QD dosing improves compliance."

-Internal Medicine

Many of the respondents also participated in an online discussion regarding various treatment strategies and shared their plans to use the newly available therapy.

The full report includes:

  • Key Findings
  • Physician Demographics
  • Discussion Highlights
  • Quantitative and Qualitative Post Analysis

Companies that are in the process of developing or have approved anticoagulants include Bayer/Johnson & Johnson, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb/Pfizer and Merck/Portola.

To download full results of this free report, visit sermo.com/client.

About Sermo Reports

Sermo Reports solicit perceptions and opinions from physicians about new drugs, devices, treatments, trends, and other topics of interest. Data for Sermo Reports is gathered through Sermo Posts, which allow physicians to participate in a poll and comment on the topic.  All physicians on Sermo are verified and credentialed.

About Sermo

Sermo is the largest online physician community, where over 117,000 practicing physicians discuss a wide range of issues from clinical cases to advice about drugs and practice management. By leveraging Sermo's social media platform, clients can tap into unsolicited, peer-to-peer dialog and engage MDs to gain market intelligence and increase brand awareness. For more information, visit www.sermo.com/client.


'/>"/>
SOURCE Sermo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sermo Report Indicates that Ticagrelor is Likely to Affect the Standard of Care for ACS Patients
2. Sermo Study Shows 63% of Physicians Would Utilize New Gout Treatments
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
10. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , January 20, 2017 Avillion LLP, ... appointment of Mark Weinberg , MD MBA as Chief Medical ... , USA . ... Dr Weinberg has spent more than 17 years ... 20" pharma companies to micro-cap biotech. Over the course of his ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 Report ... Ophthalmic Devices Market? Which areas are going to grow ... potential revenues to 2026, assessing data, trends, opportunities and ... and graphs. Discover the most lucrative areas in the ... lets you assess forecasted sales across the all the ...
(Date:1/19/2017)... 2017 Conference Call and Webcast to Follow ... it will release results for the fourth quarter of 2016 on ... ... call at 4:30 PM ET on Wednesday, February 15, 2017, during ... financial results and other corporate activities. To participate in the conference ...
Breaking Medicine Technology:
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... of its new medical office in Petaluma, located at 167 Lynch Creek Way. ... access to SRO sports medicine and rehabilitation services and on-site x-ray ...
(Date:1/20/2017)... ... 20, 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 Lift. Built ... is mounted on wheels, it can be wheeled out of the way and stored when ... the deck. "We have transformed the feedback from customers into specific enhancements and created a ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and body ... oils, announced the company had a successful visit to the 2017 ECRM Diet, Vitamin ... companies that work in the nutritional, sports and health industries a chance to meet ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company ... with school-aged children since the holiday season. , “It happens every year around ... sharing hugs and taking photos, which is the head-to-head gateway that lice need to ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 years ... Betsy, the clinical trial has been life-saving as she has been on the ... Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but ...
Breaking Medicine News(10 mins):